


(d) compounds containing pentose derivatives; and
(2) purifying the substance having an apoptosis-inducing ability from the heat-treated compound.

11. (Amended) An apoptosis-inducing compound selected from
4-(9-adeninyl)-2-cyclopenten-1-one,
4-(9-guanylyl)-2-cyclopenten-1-one,
1,5-epoxy-1-hydroxy-3-penten-2-one,
2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane, and
the compound represented by the following formula [I]



[I]

(In the formula, R is a residual group after removal of an SH group from an amino acid containing an SH group or a peptide containing an amino acid containing an SH group.)

12. (Amended) A pharmaceutical agent for therapy of a disease selected from the group consisting of cancer, rheumatism, diabetes mellitus, dwarfism, systemic hypotension, lowering in blood pressure response, autoimmune disease, inflammation, arthritis, rheumatic arthritis, inflammatory intestine diseases, insufficiency of blood vessel function, etiological dilation of blood vessel, damage of tissues, cardiovascular ischemia, sensitivity to pain, cerebral ischemia, diseases caused by angiogenesis and viral diseases, characterized in that, said pharmaceutical agent contains a compound selected from

4,5-dihydroxy-2-pental,.

4-(9-adeninyl)-2-cyclopenten-1-one,

4-(9-guaninyl)-2-cyclopenten-1-one,

2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane,

1,5-epoxy-1-hydroxy-3-penten-2-one, and

a compound represented by the formula [I]

characterized in that, said pharmaceutical agent contains a compound selected from

4,5-dihydroxy-2-pental,

4-hydroxy-2-cyclopenten-1-one,


4-(9-adleninyl)-2-cyclopenten-1-one,

4-(9-guaninyl)-2-cyclopenten-1-one,

2-(3,4-dihydroxy-1-butenyl)-4-(2-formylvinyl)-1,3-dioxolane,

1,5-epoxy-1-hydroxy-3-penten-2-one, and

a compound represented by the formula [I] as an effective component



(In the formula, R is a residual group after removal of an SH group from an amino acid containing an SH group or a peptide containing an amino acid containing an SH group).

Please cancel claims 13 and 15.

Marked Up Version Showing Changes

1. (Amended) A method for the manufacture of a substance having an apoptosis-inducing ability characterized in including [a step of] the following steps.

(1) subjecting at least one compound selected from the following (a), (b), (c) and (d)